Loading clinical trials...
Loading clinical trials...
Open Label, Single Dose, Parallel-group Study to Evaluate the PK and the Safety and Tolerability of Single Oral Doses of BI 1291583 in Trial Participants With Mild, Moderate and Severe Hepatic Impairment as Compared to Matched, Hepatically Healthy Trial Participants.
Conditions
Interventions
BI 1291583
Locations
3
United States
Orlando Clinical Research Center
Orlando, Florida, United States
Tranquil Clinical Research
Houston, Texas, United States
American Research Corporation at the Texas Liver Institute
San Antonio, Texas, United States
Start Date
June 25, 2025
Primary Completion Date
July 4, 2026
Completion Date
July 4, 2026
Last Updated
January 30, 2026
NCT07470866
NCT00104325
NCT07388667
NCT03878121
NCT05447416
NCT07090785
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions